The Motley Fool··Seena HassounaTravere Director Cashes In Near Peak, But $1.6M Stake Signals Conviction
Travere Therapeutics Director Roy Baynes sold 4,500 shares for ~$210K near 52-week highs but retained $1.6M stake, suggesting conviction despite partial exit.
TVTXinsider salestock options